Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 3 | EJNMMI Radiopharmacy and Chemistry

Fig. 3

From: Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer

Fig. 3

Representative SE-HPLC chromatograms for A BnDTPA-trastuzumab-NLS and B trastuzumab on a BioSep SEC-s4000 column (Phenomenex, Torrance, CA, USA) eluted with 100 mM NaH2PO4 buffer, pH 7.0 at a flow rate of 0.8 mL/min with UV detection at 280 nm. Trastuzumab and BnDTPA-trastuzumab-NLS exhibited one major peak with retention time (tR = 11.7 min) but BnDTPA-trastuzumab-NLS exhibited a second peak at tR = 10.6 min. This small second peak may be due to cross-linking of BnDTPA-trastuzumab after reaction with Sulfo-SMCCrequired to introduce maleimide groups for conjugation to the thiol on cysteine in NLS peptides

Back to article page